News

EC Approves MabThera Biosimilar Rixathon for Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

The European Commission (EC) has approved the use and marketing in Europe of Rixathon, a biosimilar to Roche’s MabThera (rituximab). The decision follows a positive review of Rixathon by the Committee for Medicinal Products for Human Use (CHMP) last April in response to Sandoz’s marketing application.

Nucala Triggered Remission in Eosinophilic Granulomatosis with Polyangiitis, But Not All Benefit

Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…